MIRASOL, NCT04209855 / 2019-003509-80: A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression |
|
|
| Recruiting | 3 | 430 | Europe, Canada, US, RoW | Mirvetuximab Soravtansine, MIRV, IMGN853, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin | ImmunoGen, Inc., Gynecologic Oncology Group, European Network of Gynaecological Oncological Trial Groups (ENGOT) | Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer | 12/22 | 04/24 | | |